Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

SIMPLE SUMMARY: Concurrent platinbased chemoradiotherapy followed by maintenance treatment with the PD-L1 inhibitor durvalumab is the new standard of care for inoperable stage III NSCLC. The present study compares the oncological outcome of patients treated with chemoradiotherapy to those treated wi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancers (Basel)
Huvudupphovsmän: Taugner, Julian, Käsmann, Lukas, Eze, Chukwuka, Tufman, Amanda, Reinmuth, Niels, Duell, Thomas, Belka, Claus, Manapov, Farkhad
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2021
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8037429/
https://ncbi.nlm.nih.gov/pubmed/33807324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13071613
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk